Disproportionality analysis of adverse events associated with bimekizumab: a real-world study based on FDA Adverse Event Reporting System (FAERS) Database

Bimekizumab, a humanized monoclonal antibody targeting interleukin-17A (IL-17A) and IL-17F, is approved for the treatment of multiple chronic inflammatory conditions, including plaque psoriasis and psoriatic arthritis. Nevertheless, its long-term safety profile in large-scale patient populations has not been fully characterized. To address this gap, we conducted a pharmacovigilance analysis utilizing real-world data to systematically evaluate adverse events (AEs) associated with bimekizumab...